Loading
ICP-248 is an experimental small-molecule drug from Beijing InnoCare Pharma Tech in phase 3 trials for mantle cell lymphoma and chronic lymphocytic leukaemia, with its target not yet stated publicly.
ICP-248 is a small-molecule drug developed by Beijing InnoCare Pharma Tech. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: Eligible patients will receive ICP-248 orally as per the protocol，once daily for every 28 days as one treatment cycle. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06378138 (ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma (APEX-03)), in mantle cell lymphoma and chronic lymphocytic leukaemia. The largest, NCT06378138, plans to enrol 226 participants with primary completion expected 2030-11-25. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.ICP-248 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ICP-248" OR ABSTRACT:"ICP-248") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ICP-248, not a curated reading list.
Shares InnoCare Pharma and the tag pipeline.
Shares InnoCare Pharma and the tag pipeline.
Shares InnoCare Pharma and the tag pipeline.
Shares InnoCare Pharma and the tag pipeline.
Shares InnoCare Pharma and the tag pipeline.
Shares Mantle cell lymphoma, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Mantle cell lymphoma, Chronic lymphocytic leukaemia and the tag pipeline.
Shares InnoCare Pharma and the tag pipeline.